人用药品委员会指南引言：非劣效性界值的选择与数据监测委员会，作者：大卫·布朗、彼得·沃尔克斯和西蒙·戴，《医学统计学》2006年；第25卷：第1623 - 1627页 - Suppr

Suppr

超能文献

An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.

出版信息

Stat Med. 2007 Jan 15;26(1):230-3; author reply 234-5. doi: 10.1002/sim.2665.

DOI:10.1002/sim.2665

PMID:16900566

Abstract

摘要

相似文献

An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.

Stat Med. 2007 Jan 15;26(1):230-3; author reply 234-5. doi: 10.1002/sim.2665.

An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.

Stat Med. 2006 May 30;25(10):1623-7. doi: 10.1002/sim.2561.

Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.

Stat Med. 2006 May 30;25(10):1639-45. doi: 10.1002/sim.2585.

Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.

Stat Med. 2006 May 30;25(10):1628-38. doi: 10.1002/sim.2584.

The European regulatory experience.

Stat Med. 2002 Oct 15;21(19):2931-8. doi: 10.1002/sim.1297.

[Methodological and statistical aspects of equivalence and non inferiority trials].

Rev Epidemiol Sante Publique. 2008 Aug;56(4):267-77. doi: 10.1016/j.respe.2008.05.027. Epub 2008 Aug 13.

Standard 3: data monitoring committees.

Pediatrics. 2012 Jun;129 Suppl 3:S132-7. doi: 10.1542/peds.2012-0055F.

Data safety and monitoring boards for African clinical trials.

Trans R Soc Trop Med Hyg. 2008 Dec;102(12):1189-94. doi: 10.1016/j.trstmh.2008.06.009. Epub 2008 Jul 21.

Playing safe and preserving integrity: making the FDA model work.

Stat Med. 2004 May 30;23(10):1523-5. doi: 10.1002/sim.1788.

Research review boards dogged by criticism.

Nature. 2009 Apr 2;458(7238):557. doi: 10.1038/458557b.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Stat Med. 2007 Jan 15;26(1):230-3; author reply 234-5. doi: 10.1002/sim.2665.

An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.

Stat Med. 2006 May 30;25(10):1623-7. doi: 10.1002/sim.2561.

Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.

Stat Med. 2006 May 30;25(10):1639-45. doi: 10.1002/sim.2585.

Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.

Stat Med. 2006 May 30;25(10):1628-38. doi: 10.1002/sim.2584.

The European regulatory experience.

Stat Med. 2002 Oct 15;21(19):2931-8. doi: 10.1002/sim.1297.

[Methodological and statistical aspects of equivalence and non inferiority trials].

Rev Epidemiol Sante Publique. 2008 Aug;56(4):267-77. doi: 10.1016/j.respe.2008.05.027. Epub 2008 Aug 13.

Standard 3: data monitoring committees.

Pediatrics. 2012 Jun;129 Suppl 3:S132-7. doi: 10.1542/peds.2012-0055F.

Data safety and monitoring boards for African clinical trials.

Trans R Soc Trop Med Hyg. 2008 Dec;102(12):1189-94. doi: 10.1016/j.trstmh.2008.06.009. Epub 2008 Jul 21.

Playing safe and preserving integrity: making the FDA model work.

Stat Med. 2004 May 30;23(10):1523-5. doi: 10.1002/sim.1788.

Research review boards dogged by criticism.

Nature. 2009 Apr 2;458(7238):557. doi: 10.1038/458557b.

An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.

出版信息

Stat Med. 2007 Jan 15;26(1):230-3; author reply 234-5. doi: 10.1002/sim.2665.

DOI:10.1002/sim.2665

PMID:16900566

Abstract

摘要